BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 19932574)

  • 1. Bisphosphonates and atypical femoral fractures: a time for reflection.
    Compston JE
    Maturitas; 2010 Jan; 65(1):3-4. PubMed ID: 19932574
    [No Abstract]   [Full Text] [Related]  

  • 2. What to make of the new warning on bisphosphonates. Officials acknowledge a connection between the most popular bone drugs and rare thigh fractures.
    Harv Womens Health Watch; 2010 Dec; 18(4):6-7. PubMed ID: 21268797
    [No Abstract]   [Full Text] [Related]  

  • 3. Thighbone fractures in women taking bisphosponate drugs.
    Harv Womens Health Watch; 2010 Mar; 17(7):6-7. PubMed ID: 20486271
    [No Abstract]   [Full Text] [Related]  

  • 4. More on atypical fractures of the femoral diaphysis.
    Lee P; Seibel MJ
    N Engl J Med; 2008 Jul; 359(3):317; author reply 317-8. PubMed ID: 18642421
    [No Abstract]   [Full Text] [Related]  

  • 5. Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk.
    Schneider JP
    Geriatrics; 2009 Jan; 64(1):18-23. PubMed ID: 19256578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In brief: duration of use of bisphosphonates.
    Med Lett Drugs Ther; 2011 Oct; 53(1374):77. PubMed ID: 21959355
    [No Abstract]   [Full Text] [Related]  

  • 7. Study finds no link between bone drugs and unusual thigh fractures.
    Harv Womens Health Watch; 2010 Jul; 17(11):6. PubMed ID: 20684079
    [No Abstract]   [Full Text] [Related]  

  • 8. Risk of atypical femoral fractures and osteonecrosis of the jaw associated with alendronate use compared with other oral bisphosphonates.
    Kharazmi M; Hallberg P; Warfvinge G; Michaëlsson K
    Rheumatology (Oxford); 2014 Oct; 53(10):1911-3. PubMed ID: 25099769
    [No Abstract]   [Full Text] [Related]  

  • 9. Controversies in osteoporosis management: concerns about bisphosphonates and when are "drug holidays" required?
    McClung M
    Clin Obstet Gynecol; 2013 Dec; 56(4):743-8. PubMed ID: 24177063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are bisphosphonates associated with an increased risk of atypical femoral fractures as a class?
    Pazianas M
    JAMA Intern Med; 2013 Jan; 173(1):79-80. PubMed ID: 23318593
    [No Abstract]   [Full Text] [Related]  

  • 11. [Bisphosphonates for osteoporosis].
    Narusawa K; Nakamura T
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():311-5. PubMed ID: 18161123
    [No Abstract]   [Full Text] [Related]  

  • 12. [Osteoporosis and bisphosphonates].
    Zuber MA
    Z Rheumatol; 2007 Dec; 66(8):713-5. PubMed ID: 17955251
    [No Abstract]   [Full Text] [Related]  

  • 13. Atypical diaphyseal femur fractures in patients with prolonged administration of bisphosphonate medication for osteoporosis.
    Horning JA; Czajka J; Uhl RL
    Orthopedics; 2010 Dec; 33(12):902. PubMed ID: 21117565
    [No Abstract]   [Full Text] [Related]  

  • 14. Going on a drug holiday?
    Bonnick SL
    J Clin Densitom; 2011; 14(4):377-83. PubMed ID: 22051091
    [No Abstract]   [Full Text] [Related]  

  • 15. [Is SSBT associated with atypical femoral fracture? SSBT isn't associated with atypical femoral fracture].
    Soen S
    Clin Calcium; 2012 Jun; 22(6):919-22. PubMed ID: 22653034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fracture risk associated with chronic use of bisphosphonates: evidence today.
    Charopoulos I; Orme S; Giannoudis PV
    Expert Opin Drug Saf; 2011 Jan; 10(1):67-76. PubMed ID: 21121870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Atypical femoral fractures in long-term osteoporotic treatment with bisphosphonates].
    Thein R; Tenenbaum S; Chechick O; Hershkovitz O; Chechik A; Caspi I
    Harefuah; 2012 Sep; 151(9):532-6, 555. PubMed ID: 23367748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.
    Black DM; Kelly MP; Genant HK; Palermo L; Eastell R; Bucci-Rechtweg C; Cauley J; Leung PC; Boonen S; Santora A; de Papp A; Bauer DC; ;
    N Engl J Med; 2010 May; 362(19):1761-71. PubMed ID: 20335571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Diphosphonate therapy and osteonecrosis of the jaw].
    Løkken P; Skoglund LA; Skjelbred P
    Tidsskr Nor Laegeforen; 2007 Aug; 127(15):1945-7. PubMed ID: 17700737
    [No Abstract]   [Full Text] [Related]  

  • 20. Atypical femoral fractures and their relation to bisphosphonate use.
    Tripto-Shkolnik L
    Isr Med Assoc J; 2013 Aug; 15(8):447-50. PubMed ID: 24079069
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.